Wednesday, May 04, 2022 1:41:36 PM
I have been saying since last summer that this could go to cash value. I have not looked at the recent balance sheet, but if you add in inventory, my guess is we are not that far. Sorry, but that is where we deserve to be. AMRN has failed in its strategy, and I see more pain for at least 2 years, but probably more. Tell me other than when RI was released, when any study on V had a positive effect? I could care less about any new study....IT DOESN'T MATTER!!!!
There are many things that have caused this failure...all of them are by decisions made by management. Number one is the entire board should be fired, but they just seem fine with where this is going. Let's face reality, at this point the entire board is getting reelected. I mean what the hell does it take for institutional investors to bring new board members forward? It's not looking like Denner is going to have representation on the board...but why not? Can he do any worse? Declining sales in the US, excuses in the EU and a cash burn that will require a dilution latter this year (it's going to happen) spells disaster.
We need action NOW!. No more options for anyone. Why are we hiring at all? Fire the entire US sales force. Dump the headquarters. Announce that you looking at strategic alternatives. They are not taking this to a billion a year in the EU. KM talked about real sales in the EU in 2023. They won't be $50M by then. What will sales be in the US? $200M? Sorry, but the only option is to sell the company now and take what we can get. If not, sub $1 is coming. Sorry...not adding here either...not until I actually see an accomplishment...something...anything. All I see is failure and excuses.
There are many things that have caused this failure...all of them are by decisions made by management. Number one is the entire board should be fired, but they just seem fine with where this is going. Let's face reality, at this point the entire board is getting reelected. I mean what the hell does it take for institutional investors to bring new board members forward? It's not looking like Denner is going to have representation on the board...but why not? Can he do any worse? Declining sales in the US, excuses in the EU and a cash burn that will require a dilution latter this year (it's going to happen) spells disaster.
We need action NOW!. No more options for anyone. Why are we hiring at all? Fire the entire US sales force. Dump the headquarters. Announce that you looking at strategic alternatives. They are not taking this to a billion a year in the EU. KM talked about real sales in the EU in 2023. They won't be $50M by then. What will sales be in the US? $200M? Sorry, but the only option is to sell the company now and take what we can get. If not, sub $1 is coming. Sorry...not adding here either...not until I actually see an accomplishment...something...anything. All I see is failure and excuses.
Recent AMRN News
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 04/10/2026 09:01:34 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 04/10/2026 09:00:20 PM
- American College of Cardiology (ACC) Scientific Sessions 2026 Underscore the Need for Complementary Therapies Including Icosapent Ethyl (IPE) in Treatment of Elevated Triglycerides and Cardiovascular Risk Reduction • GlobeNewswire Inc. • 04/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 04/02/2026 08:30:11 PM
- Form PRE 14A - Other preliminary proxy statements • Edgar (US Regulatory) • 03/30/2026 09:57:06 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/27/2026 09:00:07 PM
- Amarin Highlights Guideline Recommended Role of Icosapent Ethyl in Managing Cardiovascular Risk Following Release of Updated 2026 ACC/AHA/Multisociety Dyslipidemia Guideline • GlobeNewswire Inc. • 03/18/2026 12:30:00 PM
- New REDUCE-IT Data in Patients at Extreme Cardiovascular Risk and In Vitro Research on the Mechanistic Effects of Eicosapentaenoic Acid (EPA) on Lipoprotein(a) [Lp(a)] Oxidation to be Presented at the American College of Cardiology’s (ACC) Annual Scienti • GlobeNewswire Inc. • 03/16/2026 12:15:00 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 03/02/2026 10:31:01 PM
- Effects of Icosapent Ethyl on Risk and Duration of Hospitalizations and Death in REDUCE-IT® Post Hoc Analysis Published in the European Journal of Preventive Cardiology • GlobeNewswire Inc. • 03/02/2026 01:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/25/2026 12:05:26 PM
- Amarin Reports Fourth Quarter and Full Year 2025 Financial Results • GlobeNewswire Inc. • 02/25/2026 12:00:00 PM
- This American Heart Month Amarin Spotlights the Need to Prioritize Proven Widely Available Yet Underutilized Therapies in the Battle Against Cardiovascular Disease • GlobeNewswire Inc. • 02/23/2026 01:00:00 PM
- Amarin to Report Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call on February 25, 2026 • GlobeNewswire Inc. • 02/11/2026 01:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:09 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:07 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:06 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:05 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2026 12:00:04 AM
- Amarin Applauds Breakthroughs In Therapies For Patients With Elevated Triglycerides; Company’s VASCEPA®/VAZKEPA® (Icosapent Ethyl) Franchise Well Positioned To Benefit Globally From Broadened Category Commercialization • GlobeNewswire Inc. • 01/09/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/08/2026 12:05:27 PM
- Amarin Announces Preliminary 2025 Financial Highlights and Operational Accomplishments, Including Achieving Positive Cash Flow; Company Well Positioned to Capture Global Growth Opportunities • GlobeNewswire Inc. • 01/08/2026 12:00:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:21 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:17 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/06/2026 10:00:10 PM
